Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Walawander

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
The Annals of Pharmacotherapy|May 11, 1992
A nationwide investigation of a possible protamine drug-product defectC R Herrera, T H Grasela, C A Walawander
Pharmacoeconomics|October 28, 1999
Applying epidemiology-based outcomes research to clinical decision-making. A hypothetical model of biotechnology therapy in gram-negative sepsisE C Wang, T H Grasela, C A Walawander
Journal of Pharmacokinetics and Biopharmaceutics|February 1, 1991
An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysisD B White, C A Walawander, Y Tung, et al.
Journal of Pharmacokinetics and Biopharmaceutics|June 1, 1992
Evaluation of hypothesis testing for comparing two populations using NONMEM analysisD B White, C A Walawander, D Y Liu, et al.
The Annals of Pharmacotherapy|April 1, 1994
Risk factors for acute renal insufficiency in patients with suspected or documented bacterial pneumoniaL S Welage, C A Walawander, E G Timm, et al.
The Annals of Pharmacotherapy|July 1, 1994
Alternatives to intravenous tetracycline hydrochloride for malignant pleural effusionsT H Grasela, C A Walawander, H M Jolson, et al.
American Journal of Hospital Pharmacy|September 1, 1993
Capability of hospital computer systems in performing drug-use evaluations and adverse drug event monitoringT H Grasela, C A Walawander, D L Kennedy, et al.
Journal of the American Medical Directors Association|June 19, 2003
Implementation of a nursing home urinary incontinence management program with and without tolterodineJ G Ouslander, C Maloney, T H Grasela, et al.
Pharmacotherapy|January 11, 1992
Prospective evaluation of risk factors for antibiotic-associated bleeding in critically ill patientsT F Goss, C A Walawander, T H Grasela, et al.
The Annals of Pharmacotherapy|February 1, 1994
Use of antifungal therapy in hospitalized patients. I. Results prior to the marketing of fluconazoleT H Grasela, S D Goodwin, M T Pasko, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
The Annals of Pharmacotherapy|May 11, 1992
A nationwide investigation of a possible protamine drug-product defectC R Herrera, T H Grasela, C A Walawander
Pharmacoeconomics|October 28, 1999
Applying epidemiology-based outcomes research to clinical decision-making. A hypothetical model of biotechnology therapy in gram-negative sepsisE C Wang, T H Grasela, C A Walawander
Journal of Pharmacokinetics and Biopharmaceutics|February 1, 1991
An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysisD B White, C A Walawander, Y Tung, et al.
Journal of Pharmacokinetics and Biopharmaceutics|June 1, 1992
Evaluation of hypothesis testing for comparing two populations using NONMEM analysisD B White, C A Walawander, D Y Liu, et al.
The Annals of Pharmacotherapy|April 1, 1994
Risk factors for acute renal insufficiency in patients with suspected or documented bacterial pneumoniaL S Welage, C A Walawander, E G Timm, et al.
The Annals of Pharmacotherapy|July 1, 1994
Alternatives to intravenous tetracycline hydrochloride for malignant pleural effusionsT H Grasela, C A Walawander, H M Jolson, et al.
American Journal of Hospital Pharmacy|September 1, 1993
Capability of hospital computer systems in performing drug-use evaluations and adverse drug event monitoringT H Grasela, C A Walawander, D L Kennedy, et al.
Journal of the American Medical Directors Association|June 19, 2003
Implementation of a nursing home urinary incontinence management program with and without tolterodineJ G Ouslander, C Maloney, T H Grasela, et al.
Pharmacotherapy|January 11, 1992
Prospective evaluation of risk factors for antibiotic-associated bleeding in critically ill patientsT F Goss, C A Walawander, T H Grasela, et al.
The Annals of Pharmacotherapy|February 1, 1994
Use of antifungal therapy in hospitalized patients. I. Results prior to the marketing of fluconazoleT H Grasela, S D Goodwin, M T Pasko, et al.
Pageof 3